Cargando…

Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients

Dipeptidyl peptidase-4 (DPP4) is an important regulator of incretins and inflammation, and it is involved in the pathophysiological process of myocardial infarction (MI). This study investigated the role of plasma DPP4 activity (DPP4a) in patients with ST-segment elevation myocardial infarction (STE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jing Wei, Chen, Yun Dai, Chen, Wei Ren, Jing, Jing, Liu, Jie, Yang, Yong Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175165/ https://www.ncbi.nlm.nih.gov/pubmed/28000723 http://dx.doi.org/10.1038/srep39412

Ejemplares similares

The predictive value of eosinophil levels on no-reflow in patients with STEMI following PCI: a retrospective cohort study
por: Mo, De-Gang, et al.
Publicado: (2022)

Role of no reflow and microvascular obstruction in the prognostic stratification of STEMI patients
por: Durante, Alessandro
Publicado: (2018)

Clinical effect of preoperative high-dose atorvastatin against no-reflow after PCI
por: Liu, Wenbo, et al.
Publicado: (2017)

Prophylactically injection of Nicorandil to reduce no-reflow phenomenon during PCI in acute STEMI patients: Protocol of a double-blinded, randomized, placebo-controlled trial
por: An, Su, et al.
Publicado: (2021)

The abnormal level and prognostic potency of multiple inflammatory cytokines in PCI‐treated STEMI patients
por: Zhang, Jing, et al.
Publicado: (2022)

Access-Site vs Non-Access-Site Major Bleeding and In-Hospital Outcomes Among STEMI Patients Receiving Primary PCI
por: Thibert, Michael J., et al.
Publicado: (2021)

Study on Correlation between Type 2 Diabetes and No-Reflow after PCI
por: Zhao, Su-Rui, et al.
Publicado: (2022)

Predicting mortality and no‐reflow in STEMI patients using epicardial adipose tissue
por: Mohamed, Amr
Publicado: (2021)

Combined value of red blood cell distribution width and global registry of acute coronary events risk score on predicting long-term major adverse cardiac events in STEMI patients undergoing primary PCI
por: Chang, Xue-Wei, et al.
Publicado: (2018)

No-Reflow after PPCI—A Predictor of Short-Term Outcomes in STEMI Patients
por: Pantea-Roșan, Larisa Renata, et al.
Publicado: (2020)

The SALINE Technique for the Treatment of the No-Reflow Phenomenon during Percutaneous Coronary Intervention in STEMI
por: Grancini, Luca, et al.
Publicado: (2023)

Risk factors and prediction nomogram model for 1-year readmission for major adverse cardiovascular events in patients with STEMI after PCI
por: Yao, Wensen, et al.
Publicado: (2022)

Free triiodothyronine and global registry of acute coronary events risk score on predicting long-term major adverse cardiac events in STEMI patients undergoing primary PCI
por: Chang, Xuewei, et al.
Publicado: (2018)

Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction
por: Li, Jing-Wei, et al.
Publicado: (2017)

In-Hospital Peak Glycemia in Predicting No-Reflow Phenomenon in Diabetic Patients with STEMI Treated with Primary Percutaneous Coronary Intervention
por: Liu, Fang, et al.
Publicado: (2021)

Impact of periprocedural morphine use on mortality in STEMI patients treated with primary PCI
por: Domokos, Dominika, et al.
Publicado: (2021)

Calcified plaque harboring lipidic materials associates with no-reflow phenomenon after PCI in stable CAD
por: Hosoda, Hayato, et al.
Publicado: (2023)

New guidelines on primary PCI for patients with STEMI: changing insights
por: van der Wall, E.E.
Publicado: (2015)

Will intravenous paracetamol crush fentanyl in patients undergoing PCI for STEMI?
por: ten Berg, J. M., et al.
Publicado: (2019)

Effect of prehospital treatment in STEMI patients undergoing primary PCI
por: Fabris, Enrico, et al.
Publicado: (2022)

Autologous blood injection intracoronary artery for treating slow‐flow and no‐reflow in acute coronary syndrome related to primary pci
por: Truong Hoai, Lam, et al.
Publicado: (2022)

Prognostic implications and outcomes of cardiac arrest among contemporary patients with STEMI treated with PCI
por: Kumar, Anirudh, et al.
Publicado: (2021)

Relationships between circulating branched chain amino acid concentrations and risk of adverse cardiovascular events in patients with STEMI treated with PCI
por: Du, Xiaoyu, et al.
Publicado: (2018)

The association between CD69 and EGR1 levels, and CHD patients without reflow after PCI
por: Xiang, Yi, et al.
Publicado: (2019)

Effect of Chinese national holidays and weekends versus weekday admission on clinical outcomes in patients with STEMI undergoing primary PCI
por: Tang, Liang, et al.
Publicado: (2017)

Impact of COVID-19 pandemic on STEMI undergoing primary PCI treatment in Beijing, China
por: Gong, Xuhe, et al.
Publicado: (2022)

Simple clinical risk score for no-reflow prediction in patients undergoing primary Percutaneous Coronary Intervention with acute STEMI
por: Dogan, Nazile Bilgin, et al.
Publicado: (2015)

Role of tirofiban with dual antiplatelet therapy in patients with STEMI undergoing primary PCI
por: Türker, Yasin
Publicado: (2016)

Complementary Pharmacotherapy for STEMI Undergoing Primary PCI: An Evidence-Based Clinical Approach
por: Fabris, Enrico, et al.
Publicado: (2022)

BMI Modifies Increased Mortality Risk of Post-PCI STEMI Patients with AKI
por: Schvartz, Reut, et al.
Publicado: (2022)

LEFT LATERAL VIEW FOR PCI TREATMENT OF INFERIOR STEMI IN A PATIENT WITH DEXTROCARDIA
por: Katić, Josip, et al.
Publicado: (2022)

Complete revascularization with PCI in STEMI patients with multivessel disease, when is the appropriate time?
por: Aquino-Bruno, Heberto, et al.
Publicado: (2023)

Post-operative blood pressure and 3-year major adverse cardiac events in Chinese patients undergoing PCI
por: Gan, Lijun, et al.
Publicado: (2021)

Preventive PCI versus culprit lesion stenting during primary PCI in acute STEMI: a systematic review and meta-analysis
por: Pandit, Anil, et al.
Publicado: (2014)

Relationship between the duration of ischemia and final infarct size in STEMI patients treated with abciximab and primary PCI
por: Tödt, Tim, et al.
Publicado: (2012)

Relationship between treatment delay and final infarct size in STEMI patients treated with abciximab and primary PCI
por: Tödt, Tim, et al.
Publicado: (2012)

Protective effect of Danhong injection in patients with acute myocardial infarction at a high risk of no-reflow during primary percutaneous coronary intervention
por: You, Qi, et al.
Publicado: (2019)

Delayed PCI is not beneficial for STEMI patients with impaired renal function: a retrospective cohort study
por: Lao, Yi, et al.
Publicado: (2023)

Thrombosis and Major Bleeding Risk After Primary PCI Among Patients With Multivessel Coronary Artery Disease
por: Zhao, Xiaoxiao, et al.
Publicado: (2022)

A prospective, observational, multicentre study comparing tenecteplase facilitated PCI versus primary PCI in Indian patients with STEMI (STEPP—AMI)
por: Victor, Suma M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r5rlevvebth5d00eo1fneiovte